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One of the major problems of gene therapy is the efficient, specific, and targeted delivery as well as the safety of the materials
used in such systems. The specific targeted delivery of genes to the lung offers the possibility to treat a variety of specific diseases.
We developed chitosan nanoparticles with the plasmid pCEM-Luc, which contains a promoter activated by magnetic field.
Nanoparticles of 200–250 nm obtained by ionic gelation with a 99% retention rate were transfected in B16F10 cells and in vivo
in the lungs of Balb/c mice by intratracheal administration. We observed that an external magnetic field increased the expression
of the luciferase reporter gene in B16F10 cells transfected with magnetic nanoparticles and in homogenized lungs of mice which
determined differences in levels of expression between different regions of the lungs (apical or distal and left or right). The highest
levels of luciferase activity were observed in the apical left region. The magnetic nanoparticles prove an efficient delivery system to
in vitro transfection of cells and lung tissue.
1. Introduction
Lung gene therapy has attracted remarkable scientific and
biomedical interest in recent years for the treatment of a
variety of pathologies including cancer that causes around
1.3 million of deaths every year; this is due to a lack of a
successful therapy. Particularly important efforts have been
made in obtaining systems possessing cell-type specificity
for transgene delivery and regulation of its expression by
small molecules. For this purpose magnetic nanoparticles
have several advantages such as particle size and large surface
area which can be properly modified to attach with biological
agents, in addition havingmagnetic response so that they can
be manipulated by an external magnetic field gradient; this
technique is called magnetofection based on the principles
developed by Widder in the 70s and its principle is to
couple geneticmaterial to nanoparticles; the efficacy has been
demonstrated in a variety of cells [1].
In vivomagnetic fields are focused under the site required
to promote the transfection and also to carry the therapeutic
gene to an organ or a specific site within the body, offering the
possibility to developmore efficient and less invasive therapy.
Chitosan nanoparticles are an attractive pharmaceutical
delivery vehicle, because they have the capacity to protect
sensitive bioactive macromolecules from enzymatic and
chemical degradation in vivo and during storage [2].
Chitosan is a biodegradable and biocompatible polysac-
charide derived from crustacean shells and can form com-
plexes with anionic macromolecules to yield nanoparticles
[3].
A carrier system with a specific amino group, density, or
surface properties to deliver drugs plays an important role in
increasing the therapy following these mechanisms: (a) the
protein of interest can be directed at the action site without
affecting healthy tissue, (b) the protein of interest could be
protected from degradation and remain stable, and (c) the
protein of interest could be capable of prolonging the drug
at the desired site.
The aim of this workwas to develop and prove the efficacy
of a gene delivery system targeted to the lungs, using chitosan
Hindawi Publishing Corporation
Journal of Nanotechnology
Volume 2014, Article ID 313415, 5 pages
http://dx.doi.org/10.1155/2014/313415
2 Journal of Nanotechnology
nanoparticles as a vehicle, to enable expression of a luciferase
reporter gene reporter using a magnetic field.
2. Material and Methods
2.1. Materials
2.1.1. Chemicals. Chitosan (25 kDa) was purchased from
Coyotefoods Bropolymer and Biotechnology, Me´xico. Cell
culture media, fetal bovine serum, and cell culture sup-
plements were obtained from GIBCO (Grand Island, NY,
USA). Tripolyphosphate (TPP) was obtained from SIGMA
(St Louis, USA).Magnetic nanoparticles were obtainedCom-
biMag (OZ Biosciences, Marseille, France). Luciferase Assay
System was obtained from Promega (Madison, WI, USA).
Plasmid purification kit was obtained from Invitrogen (San
Diego, CA, USA).
2.1.2. Plasmid. pCEM-Luc of 5000 bp length, composed of
luciferase gene under the control of hsp70 promoter which
contains elements of response to CEM (electromagnetic
field), was obtained and characterized in our laboratory [4].
2.2. Methods
2.2.1. Production of Nanoparticles of Chitosan (CS-NPs). CS-
MNPswere formulated using the ionotropic gelation between
positively charged chitosan and negatively charged TPP as
first reported by Calvo et al., 1997 [5]. Chitosan solution
was prepared at 2mg/mL dissolved in deionized water under
stirring. TPP solution (0.84mg/mL) containing pDNA (50
and 100 𝜇g) was dropped into theCS solution in equal volume
while mixing at 900–1000 rpm/min at a room temperature
(RT). The NP suspension was gently stirred for 30min at
RT for gelation. To produce the magnetic nanoparticles
of chitosan CS-MNPs a solution of CombiMag was added
(1 𝜇L/𝜇g of DNA) to the CS-NPs.
2.2.2. Particle Morphology. The morphology and size of NPs
were performed by transmission electronmicroscopy (TEM).
One drop of the aqueous dispersion of nanoparticles was
added to a coated copper grid, air-dried in vacuum desic-
cators, and then examined under an electron microscope.
Also nanoparticles were analyzed by atomic forcemicroscopy
(MFA). For this purpose the samples were diluted with
bidistilledwater andplaced on amicroscope slide to analyzate
[6].
2.2.3. Zeta Potential. The zeta potential of nanoparticles was
measured in a phosphate buffer (pH 6) using a zetasizer
(Nanotrac U2514ZS) system.
2.2.4. In Vitro Release Studies. Adequate protection of plas-
mid DNA promoted by its encapsulation in the CS-NPs was
performed using an agarose gel tested at different plasmid-
chitosan ratios (1 : 20, 1 : 30, 1 : 40, 1 : 50, and 1 : 60) to choose
the best ratio; also plasmid DNA release was determined
by incubating the CS-NPs (1𝜇g pDNA) in PBS at 37∘C; at
appropriate time intervals samples were centrifuged and the
supernatantwas replacedwith freshmedium, and the amount
of DNA released in the supernatant was quantified in a
nanodrop (Thermo scientific nanodrop 2000).
2.2.5. Encapsulation Efficiency of Nanoparticles. The encap-
sulation efficiency (EE) was calculated by the DNA content
that in entrapped into nanoparticles as shown in the following
equation. Encapsulation efficiency (%) = Actual drug load-
ing/Theoretical drug loading × 100%.
2.2.6. In Vitro Transfection Studies in B16F10 Cell Line. Cells
were seeded 24 hours (h) prior to transfection into a 24-well
plate at a density of 1 × 104 per well in 1mL of complete
medium (DMEM containing 10% fetal bovine serum, supple-
mented with antibiotic antimicotic 1%) until confluence was
attained. CS-NPs (1𝜇g of DNA for each well) and CS-MNPs
were added to the cells, and amagnetic platewas placed under
the 24-well plate for 20minutes and incubated for 24 h at 37∘C
for luciferase assay. CS-NPs without exposition to a magnetic
field were used as a control. The cells were washed twice
with ice-cold PBS, were lysated in 100𝜇L of buffer (Promega,
Madison, WI, USA), and recovered 20𝜇L of the lysate in a
luminometer reader using the luciferase assay kit (Promega,
Madison, WI, USA). Luciferase activity in cell lysates was
expressed as relative light units (LU/min per mg of protein
in the cell lysate).
2.2.7. In Vivo Studies. 7-week-old adult (25–30 g) male
Balb/c mice were used for in vivo transfections. Mice were
anesthetized intramuscularly with xylazine (50mg/kg) and
ketamine (5–10mg/kg). The trachea was exposed through
a skin incision using a sterile surgical set-up and the
nanoparticles CS-MNPs (50 𝜇g DNA) were introduced using
a 0.5mL needle; naked plasmid was used as a control. After
transfection immediately a magnet was placed on the thorax
with an adhesive for 72 h. Mice without magnet were used as
a second control. The animal procedure was approved by the
Local Ethics Committee and carried out according to the legal
guidelines.
2.3. Detection of Luciferase Activity. Mice were sacrificed
by cervical dislocation; lungs were removed, dissected into
four regions (apical and distal of the right and left side),
and washed with PBS twice homogenized in 200𝜇L of lysis
buffer (potassium phosphate, pH 7.8, and 1mMdithiothreitol
(Sigma, St Louis, USA)) using a polypropylene micropestle,
followed by 3 cycles of freezing and thawing; then the samples
were centrifuged (16,000 g) at 4∘C for 4min and recovered
supernatant. Luciferase activity was assayed with 100 𝜇L of
lung lysate supernatant and 20𝜇L of the substrate as indicated
by the manufacturer. Luciferase activity in the mouse lung
was expressed as relative light units/mg lung lysate.
2.3.1. Statistics. Statistical analysis of the data obtained in the
evaluation of transfections was determined between groups
using ANOVA test and by the Tukey nonparametric test.
These analyses were performed using SPSS version 17.0.
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Figure 1: Transmission electron microscopy. Images of nanoparticles with the size of 100–150 nm. (a) Nanoparticles formed by
chitosan/plasmid with the size of 100–150 nm (CS-NP). (b) Nanoparticles formed by chitosan/plasmid/magnetic nanoparticle with the size
of 200–250 nm (CS-MNP).
(a) (b)
Figure 2: Atomic force microscopy. Images of nanoparticles. (a) Nanoparticles formed by chitosan/plasmid with the size of 100–150 nm. (b)
Nanoparticles formed by chitosan/plasmid/magnetic nanoparticle with the size of 200–250 nm.
3. Results and Discussion
3.1. Characterization of Chitosan-DNA Nanoparticles. CS-
NPs and CS-MNPs were formed bythe ionic gelation tech-
nique with the aim of entrapping more plasmid within the
nanostructures by extreme encapsulation. In addition TPP
was chosen as crosslinking polyanionic agent, due to its
unique properties of nontoxicity and ability to instantly form
a gel on contact with chitosan. The dropwise addition of a
precise amount of TPP into chitosan solution enabled the
formation of NPs of comparable size on the nanometer scale.
The NPs analyzed by transmission electron microscopy or
atomic force microscopy demonstrated a well-defined spher-
ical shape of 150–200 nm appropriated size (Figures 1 and
2); this is important as it has previously been demonstrated
that the shape of NPs influences the efficiency of transfection.
Spherical NPs lead to better entrapment than nanoparticles
with a different morphology. This interesting phenomenon
is related to the time taken for a cell to entrap particles with
different shapes, which varies in accordance with the volume
ratio of the NPs.
3.2. Zeta Potential. The electrostatic potential that exists at
the shear plane of a particle, which is related to both surface
charge and the local environment of the particle (the zeta (𝜉)
potential) [7] in our samples, was of −25mV with a negative
polarity.
3.3. In Vitro Release of pDNA. Developments of NPs that
are stable under extracellular environment to protect the
genetic material from serum nucleases are a major concern,
which could affect the DNA stability and consequently the
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Figure 3: Agarose gel. DNA release from chitosan-plasmid com-
plexes at different ratios.
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Figure 4: Graphical representation of released plasmid pCEM-
Luc in hours. Magnetic nanoparticles of chitosan (CS-MNPs) and
chitosan nanoparticles (CS-NPs).
transfection efficiency. On an agarose gel different plasmid-
chitosan ratios were tested and it was determined that the best
ratio was 1 : 30 to perform the NP as shown in Figure 3. The
release of pDNAefficiency of CS-NPs or CS-MNPs calculated
as previously described shows that plasmids were detected at
30min after formulation of CS-MNPs, but CS-MNPs plasmid
was detected 1 h after formulation (Figure 4).The efficiency of
encapsulation calculated was 99%.
3.4. In Vitro Transfection Efficiency of Nanoparticles for
Gene Expression. The expression of luciferase in B16F10 cells
transfected with the CS-NPs exposed to the magnetic field
increased statistically (𝑃 = 0.05) until 20,000 RLU (Relative
luciferase units) in comparison with 4,585 RLU obtained
in cells unexposed to the magnetic field. This transfection
demonstrates that the promoter of the pCEM-Luc plasmid
is activated when it is in contact with the magnetic plate.
When we transfected the cells with the CS-MNPs exposed to
magnetic plate, the levels of gene expression increased from
9,421 RLU to 100,000 RLU compared with control without
magnetic field. This magnetic nanoparticle, as gene delivery
system induced by magnetic fields, produced the highest
expression of luciferase at tenfold (Figure 5).
Although the use of magnetic nanoparticles has been
widely used with good results in gene expression [8, 9], the
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Figure 5: Determination of luciferase activity. Expression efficiency
in B16F10 cells transfected with CS-NPs or CS-MPs exposed (+MF)
or unexposed (−MF) to magnetic field.
Table 1: Data averages of the RLU expressed in the four sections of
the lungs.
Distal-L Apical-L Distal-R Apical-R
pCEM-Luc −MF 2,746 3,475 3,360 2,857
pCEM-Luc + MF 15,054 23,598 14,259 10,479
CS-MNPs + MF 21,062 33,002 27,555 17,725
use of a plasmid that can be activated bymagnetic field shows
an increased gene expression significantly.
3.5. In Vivo Transfection Efficiency of Nanoparticles for Gene
Expression. For the experiments in vivo, the naked plasmid
or CS-MNPs were administrated to mice by via intratracheal
which is a fast metohd to deliver particles to the lungs
also is secure and allows only the required doses. The lung
homogenates of control mice inoculated with pCEM-Luc
naked plasmid showed lowest levels of luciferase expres-
sion of about 3,000 RLU in the four regions of the lungs;
when applying a magnet to mice, the luciferase expression
increased statistically (𝑃 = 0.05). Obtaining a major expres-
sion in an apical left region (23,598 RLU) the other three
regions, distal left (15,054 RLU), distal right (14,259 RLU),
and right apical (10,479), showed similar levels. However
the highest levels of activity luciferase compared with the
controls (𝑃 = 0.05) were obtained by the administration
of CS-MNPs and magnet exposition on lungs of mice. The
levels of luciferase activity were in left apical region of
33,002 RLU following 27,555 RLU in right distal, 21,062 RLU
in left distal, and 17,725 RLU in right apical regions (Figure 6).
The levels of luciferase activity are resumed in the Table 1.
Those results show the efficiency of magnetic nanoparticles
as a gene delivery system, founding the highest activity in
the apical left region possibly due to the position of the
magnet.
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Figure 6: Determination of luciferase activity in vivo. Expression
of luciferase in different regions of lungs (distal-L, apical-L, distal-
R, and apical-R) transfected with naked plasmid unexposed to
a magnetic field (pCEM−MF) and exposed to a magnetic field
(pCEM+MF) or magnetic nanoparticles exposed to a magnetic field
(CS-MNPs+MF).
4. Conclusion
According to the data obtained in the present investigation
the gelation ionic method to produce CS-NPs is easy, fast and
can be stable. Nanocarriers based on chitosan produced in
this study transfected cells and tissue with good expression of
the luciferase gene and evenmore using the plasmid inducible
by the influence of a magnetic external field.
Therefore this investigation represents the experimental
support of nanocarriers based on chitosan which are ade-
quate vehicles to deliver and activate genes in the lung tissue
under the influence of a magnetic external field. Also this
study shows that the promoter in the pCEM-Luc plasmid can
be used to manipulate gene expression in lung tissue.
Data shown opens new vision to control specific expres-
sion of genes and provide the basis to propose that the
nanocarrier system based on chitosan and plasmid with
elements of activation under magnetic field could have
applications for delivery and remote control of expression of
therapeutic genes in a specific tissue.
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